CEO Margaret Alexander was paid $1,022,272 in fiscal year 2025, ↓ down 38.2% from fiscal year 2024 (SEC filing 0001628280-26-027621 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,934,699 Jeremy Levin total, FY2025 Executive Chairman and Former Chief Executive Officer — highest-paid officer; CEO Margaret Alexander: $1,022,272 | — CEO (Margaret Alexander) pay percentile vs peers | — CEO-to-median pay ratio | 90.47% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OVID's next annual pay disclosure, estimated April 27, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeremy Levin | $644,054 | $0 | $0 | $744,645 | $532,000 | $0 | $14,000 | $1,934,699 |
| Executive Chairman and Former Chief Executive Officer | ||||||||
| Margaret Alexander | 515,000 | 0 | 24,806 | 118,466 | 350,000 | 0 | 14,000 | 1,022,272 |
| President and Chief Executive Officer and Former Chief Operating Officer | ||||||||
| Jeffrey Rona | 506,892 | 0 | 24,806 | 118,466 | 305,000 | 0 | 14,000 | 969,164 |
| Chief Business & Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jeremy Levin | $1,934,699 | $2,774,102 | — | ↓ −839,403 |
| Margaret Alexander | 1,022,272 | 1,655,155 | — | ↓ −632,883 |
| Jeffrey Rona | 969,164 | 1,518,796 | — | ↓ −549,632 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Ovid Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper OVID reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses OVID in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OVID in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Jeremy Levin | Executive | $1,934,699 |
| Margaret Alexander | CEO | $1,022,272 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Barbara Duncan | Independent Director | $86,266 |
| Bart Friedman | Lead Independent Director | $105,754 |
| Karen Bernstein | Independent Director | $89,940 |
| Kevin Fitzgerald | Independent Director | $69,940 |
| Stelios Papadopoulos | Independent Director | $88,906 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Margaret Alexander | Option | 2,084 | 2.72 | — |
| Margaret Alexander | RSU | 43,750 | — | 71,312 |
| Margaret Alexander | RSU | 18,750 | — | 30,562 |
| Margaret Alexander | Option | 834 | 3.22 | — |
| Margaret Alexander | Option | 47,396 | 2.5 | — |
| Margaret Alexander | Option | 91,407 | 3.68 | — |
| Margaret Alexander | Option | 91,875 | 1.05 | — |
| Margaret Alexander | Option | 96,250 | 1.07 | — |
| Margaret Alexander | Option | 262,500 | 0.57 | — |
Our executive officer compensation structure is designed to align executive performance with long-term value creation for stockholders. It is our executive compensation strategy to align executive officer performance with strategic corporate goals and the achievement of corporate milestones. We consider the majority of executive compensation to be 'at risk' meaning such compensation is based upon performance and stock price rather than in the form of guaranteed compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLP |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 84,511,953 | 8,901,691 | 2,334,071 | 90.47% | Passed |
| 2024 | 2024-06-06 | 40,499,565 | 1,760,461 | 8,185 | 95.83% | Passed |
| 2023 | 2023-06-08 | 44,681,350 | 113,666 | 40,903 | 99.66% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 90.47%a |
| 2024 | 2024-06-06 | 95.83%b |
| 2023 | 2023-06-08 | 99.66%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "Against" this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "Against" this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bart FriedmanIndependent · Lead Independent Director · Audit Committee · Compensation Committee · Nominating and Corporate Governance Committee (Chair) | $85,814 | — | $19,940 | — | — | $105,754 |
| Karen BernsteinIndependent · Audit Committee · Compensation Committee (Chair) · Nominating and Corporate Governance Committee · Not standing for re-election | 70,000 | — | 19,940 | — | — | 89,940 |
| Stelios PapadopoulosIndependent · Audit Committee · Compensation Committee | 54,355 | — | 34,551 | — | — | 88,906 |
| Barbara DuncanIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee | 66,326 | — | 19,940 | — | — | 86,266 |
| Kevin FitzgeraldIndependent · Nominating and Corporate Governance Committee | 50,000 | — | 19,940 | — | — | 69,940 |
| Jeremy M. LevinEmployee director · Board Chair | — | — | — | — | — | 0 |
| Margaret AlexanderEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,500 / 7,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $326,495 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $326,495 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ovid Therapeutics | 2025 | Margaret Alexander | $515,000 | $24,806 | $118,466 | $350,000 | $1,022,272 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jeremy Levin | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Executive Compensation”. As printed: 1,934,699. Filing ↗machine: r2 · c42 · span 253744–253753 |
| 2 | Section 01, Margaret Alexander | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Executive Compensation”. As printed: 1,022,272. Filing ↗machine: r4 · c42 · span 259572–259581 |
| 3 | Section 01, Jeffrey Rona | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Executive Compensation”. As printed: 969,164. Filing ↗machine: r6 · c42 · span 265335–265342 |
| 4 | Section 08, Bart Friedman | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 105,754. Filing ↗machine: span 429197–429503 |
| 5 | Section 08, Karen Bernstein | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 89,940. Filing ↗machine: span 424356–424687 |
| 6 | Section 08, Stelios Papadopoulos | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 88,906. Filing ↗machine: span 430747–431052 |
| 7 | Section 08, Barbara Duncan | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 86,266. Filing ↗machine: span 425946–426251 |
| 8 | Section 08, Kevin Fitzgerald | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 69,940. Filing ↗machine: span 427491–427796 |
| 9 | Section 08, Jeremy M. Levin | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 08, Margaret Alexander | DEF 14A | 2026-04-27 | 0001628280-26-027621 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001628280-26-042396 | Item 5.07 · say-on-pay result. As reported: 90.47% (votes for as printed: 84,511,953). Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-06-07 | 0000950170-24-070673 | Item 5.07 · say-on-pay result. As reported: 95.83% (votes for as printed: 40,499,565). Filing ↗ |
| 13 | Section 06, 2023 vote | Form 8-K | 2023-06-09 | 0000950170-23-027151 | Item 5.07 · say-on-pay result. As reported: 99.66% (votes for as printed: 44,681,350). Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 326,495 + equity 0 + all other 0 = 326,495, summed across the director compensation table rows.machine: formula: Σ = 326,495 |
| 16 | Ovid Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027621 | CEO total compensation as printed in Ovid Therapeutics's own proxy. As printed: 1,022,272. Filing ↗machine: r4 · c42 · span 259572–259581 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.